Business Context and Reporting Period
This Form 8-K Current Report was filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on March 21, 2017. The report details the entry into a material definitive agreement regarding a private placement of common stock.
Key Financial Metrics
- Transaction Type: Private placement of common stock.
- Shares Issued: 1,312,000 shares.
- Price Per Share: $2.40.
- Gross Proceeds: $3,148,800.
- Placement Agent Fee: 6% of gross proceeds (paid to National Securities Corporation).
- Net Proceeds: Approximately $2,959,872 (after deducting the 6% fee).
- Reporting Period Financials: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the execution of securities purchase agreements with two accredited investors. This transaction represents a new source of capital for the company. The closing of the offering is expected to occur on or about March 27, 2017, subject to customary conditions.
Guidance, Outlook, and Risks
- Management Commentary: The company issued a press release on March 22, 2017, announcing the offering.
- Regulatory Framework: The shares are being sold pursuant to a Prospectus dated September 29, 2014, and a Prospectus Supplement as a takedown from an effective shelf registration statement (Form S-3, File No. 333-198675).
- Risks and Contingencies: The closing is contingent upon the satisfaction of customary closing conditions. The filing notes that representations and warranties in the Purchase Agreement are made solely for the benefit of the parties to that agreement.
- Unusual Items: None reported beyond the standard private placement terms.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected March 27, 2017) and confirmation of fund receipt.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions on the investors.
- Confirm the exact amount of the placement agent fee and any other transaction costs not explicitly detailed in the summary.
- Check subsequent filings for the use of proceeds and any dilution impact on existing shareholders.